KRAS mutation: from undruggable to druggable in cancer
Abstract Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted substantial attention. The understanding of...
Saved in:
Main Authors: | Lamei Huang, Zhixing Guo, Fang Wang, Liwu Fu |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Publishing Group
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/376e4538053644209dbda716fe11e25a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting the undruggable: an interview with Leila Akkari on fighting cancer by rewiring cells
Published: (2021) -
Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways.
by: Jing Tang, et al.
Published: (2013) -
Identification of a targetable KRAS-mutant epithelial population in non-small cell lung cancer
by: Giorgia Maroni, et al.
Published: (2021) -
Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer
by: Qingzhu Jia, et al.
Published: (2021) -
Using CRISPR to understand how cancer mutations happen
by: Eve H. Rogers
Published: (2021)